Inhaled iloprost for sarcoidosis associated pulmonary hypertension

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 26, Issue 2, 2009, Pages 110-120

  Baughman, Robert P ^a   Judson, M A ^b   Lower, E E ^a,c   Highland, K ^b   Kwon, S ^b   Craft, N ^b   Engel, P J ^d  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Oncology Hematology Consultants   (United States)

^d Ohio Heart Center   (United States)

Author keywords

Prostacyclins; Pulmonary hypertension; Stage 4 sarcoidosis

Indexed keywords

ILOPROST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DRUG WITHDRAWAL; FEMALE; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HUMAN; LUNG HEMODYNAMICS; LUNG SARCOIDOSIS; LUNG VASCULAR RESISTANCE; MALE; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; WALKING;

ADMINISTRATION, INHALATION; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY WEDGE PRESSURE; QUALITY OF LIFE; QUESTIONNAIRES; SARCOIDOSIS, PULMONARY; VASODILATOR AGENTS;

EID: 77649266044     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Baughman RP, Engel PJ, Meyer CA et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 108-16.
2. Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosisrelated pulmonary hypertension. Chest 2005; 128 (3): 1483-9.
3. Rizzato G, Pezzano A, Sala G, et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis 1983; 64 (2): 121-8.
4. Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 2007; 9 Suppl 2: S8-S8.
5. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61 (1): 68-74.
6. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005; 143 (4): 282-92.
7. Fisher KA, Serlin DM,Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130 (5): 1481-8.
8. Diaz-Guzman E, Farver C, Parambil J, et al. Pulmonary hypertension caused by sarcoidosis. Clin Chest Med 2008; 29 (3): 549-63.
9. Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant 2008; 27 (3): 329-34.
10. Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of Sarcoidosis-Associated Pulmonary Hypertension: A Two-Center Experience. Chest 9 A.D.; 135: 1455-61.
11. Ventetuolo CE, Benza RL, Peacock AJ, et al. Surrogate and combined end points in pulmonary arterial hypertension. Proc Am Thorac Soc 2008; 5 (5): 617-22.
12. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132 (1): 207-13.
13. Heresi GA, Dweik RA. Sarcoidosis-associated pulmonary hypertension. One size does not fit all. Chest 2009; 135 (6): 1410-2.
14. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16 (Sep): 149-73.
15. Jones PW,Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145 (6): 1321-7.
16. Cox CE, Donohue JF, Brown CD, et al. The sarcoidosis health questionnaire. A new measure of health-related quality of life. Am J Resp Crit Care Med 2003; 168: 323-329.
17. de Vries J, Michielsen H, van Heck GL, et al. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004; 9 (Pt 3): 279-91.
18. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159 (1): 179-87.
19. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. Br Med J 1961; 4: 1165-72.
20. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342 (25): 1866-70.
21. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32 (2): 296-302.
22. Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120 (3): 866-72.
23. Distler O, Behrens F, Pittrow D, et al. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum 2008; 59 (6): 867-75.
24. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 2000; 132 (6): 435-43.
25. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174 (11): 1257-63.
26. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60 (1): 32-8.
27. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51 (2): 161-9.
28. Chen H,Taichman DB, Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc 2008; 5 (5): 623-30.
29. Taichman DB, Shin J, Hud L, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005; 6: 92-92.
30. Zlupko M, Harhay MO, Gallop R, et al. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med 2008; 102 (10): 1431-8.
31. Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169 (4): 441-7.
32. Ferrer M,Villasante C, Alonso J, et al. Interpretation of quality of life scores from the St George's Respiratory Questionnaire. Eur Respir J 2002; 19 (3): 405-13.
33. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149 (8): 521-30.
34. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008; 133 (5): 1189-95.
35. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19 (2): 217-24.
36. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347 (5): 322-9.
37. Girgis RE, Frost AE, Hill NS, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2007; 66 (11): 1467-72.
38. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114 (14): 1482-9.
39. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129 (5): 1246-52.
40. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160 (2): 600-7.
41. Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19 (3): 198-204.
42. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-9.
43. Shorr AF,Torrington KG, Hnatiuk OW. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest 2001; 120 (3): 881-6.
44. Hardy C, Robinson C, Lewis RA, et al. Airway and cardiovascular responses to inhaled prostacyclin in normal and asthmatic subjects. Am Rev Respir Dis 1985; 131 (1): 18-21.
45. Ghofrani HA,Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360 (9337): 895-900.